Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jul 23, 2020- Apple‡ smartphone-compatible digital health tool fits within the company's broader NeuroSphere™ Digital Care connected care management platform, which is designed to optimize care for chronic pain and movement disorders- NeuroSphere Digital Care offers flexible virtual care options as the COVID-19 global pandemic impacts how healthcare is administered- Approval of the Patient Controller app is the latest launch under the NeuroSphere Digital Care(1) platform- Jul 16, 2020- Worldwide sales of $7.3 billion in the second quarter, including $615 million of COVID-19 diagnostic testing-related sales- Growth rates in business areas initially most impacted by COVID-19 improved significantly over the course of the second quarter- Abbott continues to strengthen its portfolio with several recent regulatory approvals, including FreeStyle Libre 2, TriClip and Gallant heart devices
- Jul 6, 2020- Next-generation Gallant™ implantable cardioverter defibrillator family of devices offers Bluetooth® capability for a more meaningful connection between patients and their doctors- Gallant ICD and CRT-D devices feature a patient-preferred design without compromising on battery longevity and compatibility with magnetic resonance imaging (MRI)
- Jun 26, 2020-- Using optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI), physicians were able to select the right size stents and place them with greater precision-- Imaging techniques such as OCT have been shown to improve outcomes during stenting procedures¹, but remain underutilized in global clinical settings due to lack of awareness-- OCT is a high-resolution, infrared light-based imaging technique that provides unparalleled accuracy for physicians during stent implantation
- Jun 25, 2020- New data reinforce Abbott's leadership in minimally invasive treatment options for mitral and tricuspid repair and replacement therapies- Eleven late-breaking presentations at the PCR e-Course showcase impact of Abbott's innovative structural heart portfolio on patient outcomes and quality of life in real-world and clinical settings
- May 8, 2020- Researchers found the test to have 99.9% specificity and 100% sensitivity for patients tested 17 days or more after symptoms began- More than 10 million ARCHITECT antibody tests already have been shipped to hospitals and labs around the world
Apr 27, 2020-- New authorization from Health Canada allows FreeStyle Libre system to be used by frontline healthcare workers in hospitals to remotely monitor patients' glucose status to minimize exposure during COVID-19 and preserve use of personal protective equipment (PPE)-- Abbott will donate 3,000 FreeStyle Libre sensors to Canadian hospitals in need to help accelerate access to technology- Apr 16, 2020- First-quarter sales growth of 2.5 percent; organic sales growth of 4.3 percent- Recently launched three breakthrough diagnostics tests for coronavirus (COVID-19)
Apr 15, 2020- This adds to Abbott's previously announced COVID-19 molecular tests: the m2000™ lab-based test and ID NOW™ rapid point-of-care test- New antibody test will run on Abbott's ARCHITECT® i1000SR and i2000SR laboratory instruments and will expand to its new Alinity™ i system- Abbott begins shipping tomorrow and intends to distribute 4 million tests in April, ramping to 20 million in the U.S. per month in June and beyond
Apr 8, 2020-- More than 50% of people with diabetes who have been diagnosed with COVID-19 are hospitalized, according to a report from the Centers for Disease Control and Prevention (CDC)¹-- FreeStyle Libre 14 day system can be used by frontline healthcare workers in hospitals to remotely monitor patients with diabetes who can scan² to minimize exposure to COVID-19 and preserve use of personal protective equipment (PPE)-- In partnership with the American Diabetes Association (ADA), Abbott will donate 25,000 FreeStyle Libre 14 day sensors to U.S. hospitals and medical centers in outbreak hotspots to help accelerate access to technology- Feb 20, 2020- Data at ATTD reinforce and add to a growing body of clinical research and real-world evidence from users of the FreeStyle Libre system around the world- People in Germany living with Type 1 or Type 2 diabetes on insulin showed a sustained reduction in HbA1c over one year following use of the FreeStyle Libre technology
Feb 19, 2020- Collaboration will combine Abbott's leading continuous glucose monitoring (CGM) technology with Insulet's Omnipod Horizon™ Automated Insulin Delivery System to offer an accurate, easy-to-use, integrated digital health platform- Integrated technology will provide people living with diabetes around the world an affordable, transformational experience for improved glucose control- Jan 22, 2020- Fourth-quarter sales growth of 7.1 percent; organic sales growth of 8.5 percent- Fourth-quarter GAAP EPS growth from continuing operations of 59.5 percent and adjusted EPS growth from continuing operations of 17.3 percent- Several businesses achieved double-digit sales growth- Forecast reflects continued top-tier sales and earnings growth for 2020
-
Oct 22, 2019- One-third of Americans have heard someone say: "I drive better when I've smoked marijuana"- While drunk driving is on the decline, drug-impaired driving is on the rise[1]- Eleven states and Washington, DC, have legalized marijuana for recreational use; Illinois, Michigan are two of the next states to begin adult-use sales in 2020
- Oct 16, 2019- Third-quarter sales growth of 5.5 percent; organic sales growth of 7.6 percent- Exceptional growth across key platforms of FreeStyle Libre, MitraClip and Alinity- Continues to strengthen portfolio with a steady cadence of new product approvals, reimbursement coverage and clinical data
- Sep 26, 2019- Proclaim™ XR neurostimulation system uses Abbott's proprietary, low energy BurstDR™ therapy coupled with the BoldXR™ low dosing protocol for safe, effective pain relief and a battery that lasts up to 10 Years*- More than 50 million people in the United States are affected by chronic pain- Abbott's low-dose and low-energy pain management technology is designed to provide pain relief and improve system longevity, offering patients a life-altering option for pain relief without the hassles of recharging
- Sep 10, 2019- New research found Abbott's algorithm created through machine learning could give doctors a more individualized calculation, leveraging factors such as age, sex and the changing dynamics of troponin protein levels in the blood, to improve heart attack diagnosis- This technology is the first machine learning developed algorithm that combines high sensitive troponin testing with other patient details to help doctors better determine if a heart attack is occurring
- Aug 26, 2019- The TRACK-TBI study found that 64% of people with the highest levels of a protein in the blood were confirmed to have brain injury through an MRI scan, even when a CT scan did not detect it- Abbott's diagnostic test, currently in development, is poised to be the first point-of-care blood test for assessing concussions on its next generation i-STAT™ device, providing doctors results in 15 minutes
- Aug 26, 2019- On Women's Equality Day, Abbott is publishing a blueprint for creating a high school STEM internship aimed at exposing young people, particularly girls, to STEM early and empowering other companies to download and use it- More than half of girls in a YouGov-Abbott survey say they aren't encouraged to study STEM, but 89% of girls who are urged to study STEM say they plan to pursue it in their educations
- Jul 17, 2019- Accelerated and sustainable growth driven by strong performance across portfolio- Raising full-year guidance for organic sales growth to 7 to 8 percent- Double-digit EPS growth exceeded expectations; raising full-year forecast- Long-term growth drivers - FreeStyle Libre, MitraClip and Alinity - achieving exceptional growth
- Jul 15, 2019- U.S. approval for MitraClip G4 offers a next-generation approach to mitral valve repair- G4 includes new clip sizes and an enhanced leaflet grasping feature
-
Jun 18, 2019- Heart failure is a manageable condition, especially if it is detected early, but people are shying away from a conversation with their doctor because they are afraid of the diagnosis- Abbott, the global leader in heart failure treatment and technologies, is using this information to increase awareness and patient-physician dialogue as heart failure diagnoses are expected to rise 46% by 2030